TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15629974

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (BB-12)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (no probiotics)
Number of subjects: 201
Study: 12127119

Group type: EXPERIMENTAL
Intervention: Total fundoplication (Nissen-Rossetti)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Partial fundoplication (Toupet)
Number of subjects: 137
Study: 10327507

Group type: EXPERIMENTAL
Intervention: Active Back School
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 8578800

Group type: EXPERIMENTAL
Intervention: rgp160 vaccine in two accelerated schedules (Groups 1 and 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rgp160 vaccine at 0, 1, 6, and 12 months (Groups 3 and 4)
Number of subjects: 0
Study: 1774408

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of midazolam and alfentanil
Number of subjects: 0
Study: 7037105

Group type: EXPERIMENTAL
Intervention: Endoscopic injection of oesophageal varices (group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tamponade only (group 1)
Number of subjects: 100
Study: 29338151

Group type: EXPERIMENTAL
Intervention: Oral prolonged-release oxycodone/naloxone (OXN) 10 +10 +5 mg every 12 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (IVPCA) 2 mg bolus, no basal infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (IVPCA)
Number of subjects: 0
Study: 27670400

Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment (ABT)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 190
Study: 25335250

Group type: EXPERIMENTAL
Intervention: Smoothing-liver and regulating-spleen method (Group A)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Regulating Governor Vessel method (Group B)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Estazolam tablets (1 mg each day for 30 days) (Group C)
Number of subjects: 156
Study: 23986168

Group type: EXPERIMENTAL
Intervention: One injection of 36 Units of AbobotulinumtoxinA (ABO) into the middle of the lateral orbital rhytides
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three intradermal injections of 12 Units each of AbobotulinumtoxinA (ABO) along the lateral canthal area
Number of subjects: 40
Study: 20332416

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18467912

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by placebo for 3 weeks (EAC and placebo)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by esomeprazole (20 mg) once daily for 3 weeks (EAC and E20)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Esomeprazole (20 mg) once daily for 3 weeks after 1 week of esomeprazole (20 mg) bid and placebo antimicrobials (E20 bid and E20)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: EAC and E20
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: EAC and placebo
Number of subjects: 401

Group type: COMPARATOR
Intervention: E20 bid and E20
Number of subjects: 401
Study: 16615116

Group type: EXPERIMENTAL
Intervention: Cereal supplement containing folic acid and wheat bran fiber (WBF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multivitamin users
Number of subjects: 0
Study: 12826544

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 68
Study: 10944557

Group type: EXPERIMENTAL
Intervention: Multidisciplinary genetic and surgical assessment service
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Current service provisions (without genetic assessment)
Number of subjects: 1000
Study: 8824962

Group type: EXPERIMENTAL
Intervention: Bladder irrigation with amphotericin B
Number of subjects: 109

Group type: COMPARATOR
Intervention: Oral fluconazole
Number of subjects: 109
Study: 1554120

Group type: EXPERIMENTAL
Intervention: Propofol (10 mg = 1 mL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (1 mL Intralipid)
Number of subjects: 52
Study: 3916838

Group type: EXPERIMENTAL
Intervention: Thymomodulin (TM), 1 ampoule b.i.d. per os for 30 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30661011

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led stress inoculation training integrated with exercise (n=53)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Guideline-based exercise alone (n=55)
Number of subjects: 108
Study: 28575484

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusion trigger < 10 g/dL, Group 1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion trigger ≤ 7 g/dL, Group 2)
Number of subjects: 160
Study: 26563117

Group type: EXPERIMENTAL
Intervention: 10 g L-arginine supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no L-arginine supplementation)
Number of subjects: 8
Study: 24714783

Group type: EXPERIMENTAL
Intervention: Matrix-applied characterized autologous cultured chondrocytes (MACI)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Microfracture (MFX)
Number of subjects: 144
Study: 22614148

Group type: EXPERIMENTAL
Intervention: 6 g·d⁻¹ CLA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20456751

Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU subcutaneously once daily for 8 days, followed by bemiparin for 20 additional days)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Placebo (after initial 8 days of bemiparin)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study: 18947359

Group type: EXPERIMENTAL
Intervention: Hot group (high-craving first session)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cold group (low-craving first session)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Comparison group (experienced high-craving session only)
Number of subjects: 98
Study: 15592872

Group type: EXPERIMENTAL
Intervention: IgG(4) antibodies to mink and silver fox urine
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Positive skin prick tests to fur urine allergens
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: IgG(4) levels
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: IgG(4) antibodies
Number of subjects: 387
Study: 11846201

Group type: EXPERIMENTAL
Intervention: Mucogingival bilaminar technique (BT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined periodontal regenerative technique (CPRT)
Number of subjects: 45
Study: 10025425

Group type: EXPERIMENTAL
Intervention: AD+DLB
Number of subjects: 160

Group type: COMPARATOR
Intervention: pure AD
Number of subjects: 160
Study: 7793402

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone (mean maintenance dose 268 ± 100 mg/day)
Number of subjects: 110
Study: 1323545

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA), 75 mg sustained release
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) in extended phase
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo in extended phase
Number of subjects: 101
Study: 364616

Group type: EXPERIMENTAL
Intervention: Ketoprofen (75 mg daily orally and 100 mg suppository at night)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Indomethacin (same dosage as ketoprofen)
Number of subjects: 50
Study: 31952456

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for ultrasound features
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for US classification systems
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for nodule US features
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for US classification systems
Number of subjects: 100
Study: 30910144

Group type: EXPERIMENTAL
Intervention: Eryngo (5 ml syrup, 3 times a day for 5 days)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg, 3 times a day for 5 days)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo (5 ml syrup, 3 times a day for 5 days)
Number of subjects: 169
Study: 29085773

Group type: EXPERIMENTAL
Intervention: verum iTBS
Number of subjects: 44

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CBT (both groups)
Number of subjects: 44
Study: 26051570

Group type: EXPERIMENTAL
Intervention: Probiotics (PRO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 46
Study: 23641782

Group type: EXPERIMENTAL
Intervention: Pre-operative neuromuscular training program (8-24 training sessions plus 3 educational sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Attention control program (3 educational sessions only)
Number of subjects: 80
Study: 16459218

Group type: EXPERIMENTAL
Intervention: Asynchronous, multi‐media, interactive, case‐based, online CME program (minimum of 4 hours)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no CME)
Number of subjects: 52
Study: 15253848

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (5 weeks, 10 sessions, 10-15 needle insertions per session, needles left in situ for 30-45 minutes)
Number of subjects: 21
Study: 10962122

Group type: EXPERIMENTAL
Intervention: Electrocardiography (ECG)
Number of subjects: 301
Study: 9192551

Group type: EXPERIMENTAL
Intervention: E2 protocol (oral care instructions at 1 week before radiotherapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no oral care instructions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E1 protocol (oral care instructions at 1 day before radiotherapy)
Number of subjects: 30
Study: 8237937

Group type: EXPERIMENTAL
Intervention: alpha-interferon (alfa-2b, 10 million units three times weekly)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 47
Study: 4035073

Group type: EXPERIMENTAL
Intervention: Short course of cyclophosphamide IV 5 mg/kg daily for 6 days immediately after mastectomy
Number of subjects: 507

Group type: COMPARATOR
Intervention: Delayed adjuvant course of cyclophosphamide IV 5 mg/kg daily for 6 days given 2-4 weeks after mastectomy
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Short multidrug course immediately after mastectomy followed by IV CMF for 1 year for axillary node-positive cases
Number of subjects: 507

Group type: COMPARATOR
Intervention: Prolonged treatment with IV CMF for 1 year
Number of subjects: 507
Study: 30366156

Group type: EXPERIMENTAL
Intervention: HD-CE (high-definition colonoscopy with 0.4% indigo carmine panchromoendoscopy)
Number of subjects: 86

Group type: COMPARATOR
Intervention: HD-WLE (high-definition white-light endoscopy)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: HD-CE
Number of subjects: 86

Group type: COMPARATOR
Intervention: HD-WLE
Number of subjects: 86
Study: 28074489

Group type: EXPERIMENTAL
Intervention: Edasalonexent (6000 mg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Edasalonexent (single dose)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Edasalonexent
Number of subjects: 104
Study: 27178707

Group type: EXPERIMENTAL
Intervention: Risk-based intervention conditions (varied by content and format)
Number of subjects: 2918

Group type: EXPERIMENTAL
Intervention: Exemplars within risk-based interventions
Number of subjects: 2918

Group type: EXPERIMENTAL
Intervention: All risk-based interventions
Number of subjects: 2918
Study: 24926999

Group type: EXPERIMENTAL
Intervention: Community-based voluntary mobile counseling and testing (CBVCT) intervention
Number of subjects: 43292

Group type: COMPARATOR
Intervention: Standard voluntary counseling and testing (SVCT)
Number of subjects: 43292
Study: 22951697

Group type: EXPERIMENTAL
Intervention: Candibiotic
Number of subjects: 80
Study: 19403504

Group type: EXPERIMENTAL
Intervention: Dopamine (2.5‐10 microg/kg per minute) or Epinephrine (0.125‐0.5 microg/kg per minute)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no cardiovascular support)
Number of subjects: 130
Study: 17501979

Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts (ABG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Distraction osteogenesis (DO)
Number of subjects: 17
Study: 15065950

Group type: EXPERIMENTAL
Intervention: Wisconsin Inventory of Smoking Dependence Motives (WISDM-68)
Number of subjects: 775
Study: 11595068

Group type: EXPERIMENTAL
Intervention: Regimen A (isoniazid, rifampicin, ethambutol for 2 months, followed by isoniazid and rifampicin for 7 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Regimen B (isoniazid, pyrazinamide, ethambutol, and ofloxacin for 2 months, followed by isoniazid, ethambutol, and ofloxacin for 10 months)
Number of subjects: 31
Study: 9643160

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg or 6 mg with Hydrochlorothiazide 25 mg added
Number of subjects: 23
Study: 8133729

Group type: EXPERIMENTAL
Intervention: Standard Bruce protocol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Modified Bruce protocol
Number of subjects: 32
Study: 2799743

Group type: EXPERIMENTAL
Intervention: Breathing exercises (group 1)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Incentive spirometer (group 2)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups (general outcome)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups (FRC on day 2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups (FRC on day 5)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups (arterial oxygen tension on day 2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups (arterial oxygen tension on day 4)
Number of subjects: 110
Study: 15830475

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 18
Study: 30569637

Group type: EXPERIMENTAL
Intervention: High dose NS-0200 (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 28345429

Group type: EXPERIMENTAL
Intervention: Intravenous 1000 mg uric acid
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25963345

Group type: EXPERIMENTAL
Intervention: Avandamet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uptitrated Metformin
Number of subjects: 0
Study: 23659360

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both stimulants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Shift from inferior drug to best drug
Number of subjects: 36
Study: 21680859

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (C‐MAC®)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional Macintosh blade laryngoscope
Number of subjects: 93
Study: 19797474

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 446

Group type: COMPARATOR
Intervention: N95 respirator
Number of subjects: 446
Study: 16428745

Group type: EXPERIMENTAL
Intervention: PTL-003
Number of subjects: 40

Group type: COMPARATOR
Intervention: PTL-002
Number of subjects: 40
Study: 15325933

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study: 11511328

Group type: EXPERIMENTAL
Intervention: Heliox (helium and oxygen mixture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heliox therapy
Number of subjects: 0
Study: 9402845

Group type: EXPERIMENTAL
Intervention: CEOP/IMVP-Dexa chemotherapy and filgrastim (self-injected at 5 micrograms/kg body weight s.c. daily, except on cytotoxic drug days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CEOP/IMVP-Dexa chemotherapy alone
Number of subjects: 85
Study: 7687509

Group type: EXPERIMENTAL
Intervention: Relevant foods (foods eliciting positive skin-prick tests and positive oral challenges)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Non-relevant foods (foods eliciting positive skin tests but negative oral challenges)
Number of subjects: 6
Study: 3323262

Group type: EXPERIMENTAL
Intervention: Trimipramine (up to 100 mg twice daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to 100 mg twice daily)
Number of subjects: 34
Study: 30415890

Group type: EXPERIMENTAL
Intervention: Oral inosine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetically engineered mice (UOx gKO, cKO, Tg)
Number of subjects: 0
Study: 27400949

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-MSCs control group
Number of subjects: 0
Study: 24314813

Group type: EXPERIMENTAL
Intervention: Well-fitted compression garments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional shorts (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loose-fitted compression garment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyes open condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyes closed condition
Number of subjects: 0
Study: 22748821

Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Glimepiride (1-4 mg)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1552
Study: 20499017

Group type: EXPERIMENTAL
Intervention: Intensive insulinotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional insulinotherapy
Number of subjects: 50
Study: 18246290

Group type: EXPERIMENTAL
Intervention: Secondary 2 Program (Tier 1 Program)
Number of subjects: 0
Study: 15699297

Group type: EXPERIMENTAL
Intervention: Telephone-based continuing care (TEL)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Standard group counseling (STND)
Number of subjects: 359
Study: 14514402

Group type: EXPERIMENTAL
Intervention: Dermabrasion (A group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional tangential excision (B group)
Number of subjects: 50
Study: 11022057

Group type: EXPERIMENTAL
Intervention: Risk factors for atherosclerosis (hypertension, dyslipidemia, diabetes mellitus, smoking)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal controls (age- and sex-matched)
Number of subjects: 117
Study: 8998023

Group type: EXPERIMENTAL
Intervention: Enhanced professional practice model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One unit's cost savings
Number of subjects: 0
Study: 1379576

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Dextran-70
Number of subjects: 216
Study: 6660435

Group type: EXPERIMENTAL
Intervention: Intranasal verapamil, 1 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31964164

Group type: EXPERIMENTAL
Intervention: Case manager-assisted rehabilitation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual physical rehabilitation
Number of subjects: 82
Study: 31725644

Group type: EXPERIMENTAL
Intervention: Chaihu-Shugan-San (CHSGS) capsule
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Tadalafil oral pharmacotherapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CHSGS capsule
Number of subjects: 135
Study: 28735699

Group type: EXPERIMENTAL
Intervention: Medication (sertraline)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (Coping Cat)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Combination of medication and cognitive-behavioral therapy
Number of subjects: 438

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: SCARED-Parent
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: SCARED-Youth
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: SCARED-Parent (children)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: SCARED-Parent (adolescents)
Number of subjects: 438
Study: 26003022

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon (PEB)
Number of subjects: 402
Study: 23132203

Group type: EXPERIMENTAL
Intervention: Care Pathways (CPs)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 581
Study: 21645330

Group type: EXPERIMENTAL
Intervention: Multicomponent pharmacological management protocol for delirium (PMD) including low-dose haloperidol at 0.5-1 mg for 7 days
Number of subjects: 428

Group type: COMPARATOR
Intervention: No change in usual ICU care
Number of subjects: 428
Study: 19958132

Group type: EXPERIMENTAL
Intervention: Japanese‐style active acupuncture
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 14
Study: 17082828

Group type: EXPERIMENTAL
Intervention: MEDLINE-first (protocol A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MEDLINE-last (protocol B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 32
Study: 11815505

Group type: EXPERIMENTAL
Intervention: Sulfonylurea + insulin
Number of subjects: 826

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 826
Study: 10408585

Group type: EXPERIMENTAL
Intervention: Exercise (E = 50 min @ 50% VO2 max)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-exercise control day (C)
Number of subjects: 46
Study: 7575256

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin solution
Number of subjects: 248

Group type: COMPARATOR
Intervention: Fortified antibiotics (1.5% tobramycin and 10.0% cefazolin solutions)
Number of subjects: 248